Ostrom QT, Wright CH, Barnholtz-Sloan JS. Brain metastases: epidemiology. Handb Clin Neurol. 2018;149:27–42. https://doi.org/10.1016/B978-0-12-811161-1.00002-5.
Article
PubMed
Google Scholar
Le Rhun E, Guckenberger M, Smits M, et al. EANO–ESMO clinical practice guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours. Ann Oncol. 2021. https://doi.org/10.1016/j.annonc.2021.07.016.
Article
PubMed
Google Scholar
Nabors LB, Portnow J, Ahluwalia M, et al. Central nervous system cancers, version 3.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18(11):1537–70. https://doi.org/10.6004/jnccn.2020.0052.
Article
PubMed
Google Scholar
Grade Definitions. US Preventive Services Task Force. 2016. https://www.uspreventiveservicestaskforce.org/Page/Name/grade-definitions.
Hempen C, Weiss E, Hess CF. Dexamethasone treatment in patients with brain metastases and primary brain tumors: do the benefits outweigh the side-effects? Support care cancer Off J Multinatl Assoc Support Care Cancer. 2002;10(4):322–8. https://doi.org/10.1007/s00520-001-0333-0.
Article
Google Scholar
Rudà R, Mo F, Pellerino A. Epilepsy in brain metastasis: an emerging entity. Curr Treat Options Neurol. 2020;22(2):6. https://doi.org/10.1007/s11940-020-0613-y.
Article
PubMed
Google Scholar
Sepúlveda-Sánchez JM, Conde-Moreno A, Barón M, Pardo J, Reynés G, Belenguer A. Efficacy and tolerability of lacosamide for secondary epileptic seizures in patients with brain tumor: a multicenter, observational retrospective study. Oncol Lett. 2017;13(6):4093–100. https://doi.org/10.3892/ol.2017.5988.
CAS
Article
PubMed
PubMed Central
Google Scholar
Maschio M, Maialetti A, Mocellini C, et al. Effect of brivaracetam on efficacy and tolerability in patients with brain tumor-related epilepsy: a retrospective multicenter study. Front Neurol. 2020;11:813. https://doi.org/10.3389/fneur.2020.00813.
Article
PubMed
PubMed Central
Google Scholar
Walbert T, Harrison RA, Schiff D, et al. SNO and EANO practice guideline update: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Neuro Oncol. 2021;23(11):1835–44. https://doi.org/10.1093/neuonc/noab152.
Article
PubMed
Google Scholar
Mills MN, Figura NB, Arrington JA, et al. Management of brain metastases in breast cancer: a review of current practices and emerging treatments. Breast Cancer Res Treat. 2020;180(2):279–300. https://doi.org/10.1007/s10549-020-05552-2.
Article
PubMed
Google Scholar
Murthy RK, Loi S, Okines A, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;382(7):597–609. https://doi.org/10.1056/NEJMoa1914609.
CAS
Article
PubMed
Google Scholar
Hurvitz SA, Saura C, Oliveira M, et al. Efficacy of neratinib plus capecitabine in the subgroup of patients with central nervous system involvement from the NALA trial. Oncologist. 2021;26(8):e1327–38. https://doi.org/10.1002/onco.13830.
CAS
Article
PubMed
PubMed Central
Google Scholar
Modi S, Saura C, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382(7):610–21. https://doi.org/10.1056/NEJMoa1914510.
CAS
Article
PubMed
Google Scholar
Li X, Yang J, Peng L, et al. Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. Breast Cancer Res Treat. 2017;161(2):279–87. https://doi.org/10.1007/s10549-016-4059-6.
Article
Google Scholar
Venur VA, Ahluwalia MS. Targeted therapy in brain metastases: ready for primetime? Am Soc Clin Oncol Educ book Am Soc Clin Oncol Annu Meet. 2016;35:e123–30. https://doi.org/10.1200/EDBK_100006.
Article
Google Scholar
Duchnowska R, Jarząb M, Żebracka-Gala J, et al. Brain metastasis prediction by transcriptomic profiling in triple-negative breast cancer. Clin Breast Cancer. 2017;17(2):e65–75. https://doi.org/10.1016/j.clbc.2016.08.008.
CAS
Article
PubMed
Google Scholar
Lv Y, Ma X, Du Y, Feng J. Understanding patterns of brain metastasis in triple-negative breast cancer and exploring potential therapeutic targets. Onco Targets Ther. 2021;14:589–607. https://doi.org/10.2147/OTT.S293685.
Article
PubMed
PubMed Central
Google Scholar
Bart J, Nagengast WB, Coppes RP, et al. Irradiation of rat brain reduces P-glycoprotein expression and function. Br J Cancer. 2007;97(3):322–6. https://doi.org/10.1038/sj.bjc.6603864.
CAS
Article
PubMed
PubMed Central
Google Scholar
Lin NU. Breast cancer brain metastases: new directions in systemic therapy. Ecancermedicalscience. 2013;7:307. https://doi.org/10.3332/ecancer.2013.307.
Article
PubMed
PubMed Central
Google Scholar
Ekenel M, Hormigo AM, Peak S, Deangelis LM, Abrey LE. Capecitabine therapy of central nervous system metastases from breast cancer. J Neurooncol. 2007;85(2):223–7. https://doi.org/10.1007/s11060-007-9409-0.
CAS
Article
PubMed
Google Scholar
Long GV, Keff RF, Phd R, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(13):1087–95. https://doi.org/10.1016/S1470-2045(12)70431-X.
CAS
Article
PubMed
Google Scholar
McArthur GA, Maio M, Arance A, et al. Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study. Ann Oncol Off J Eur Soc Med Oncol. 2017;28(3):634–41. https://doi.org/10.1093/annonc/mdw641.
CAS
Article
Google Scholar
Davies MA, Saiag P, Robert C, et al. Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol. 2017;18(7):863–73. https://doi.org/10.1016/S1470-2045(17)30429-1.
CAS
Article
PubMed
PubMed Central
Google Scholar
Long GV, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet (London, England). 2015;386(9992):444–51. https://doi.org/10.1016/S0140-6736(15)60898-4.
CAS
Article
Google Scholar
Ahmed KA, Abuodeh YA, Echevarria MI, et al. Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy. Ann Oncol. 2016;27(12):2288–94. https://doi.org/10.1093/annonc/mdw417.
CAS
Article
PubMed
PubMed Central
Google Scholar
Long GV, Atkinson V, Lo S, et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol. 2018;19(5):672–81. https://doi.org/10.1016/S1470-2045(18)30139-6.
CAS
Article
PubMed
Google Scholar
Tawbi HA, Forsyth PA, Algazi A, et al. Combined nivolumab and Ipilimumab in melanoma metastatic to the Brain. N Engl J Med. 2018;379(8):722–30. https://doi.org/10.1056/NEJMoa1805453.
CAS
Article
PubMed
PubMed Central
Google Scholar
Tawbi HA, Forsyth PA, Hodi FS, et al. Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204). Neuro Oncol. 2021. https://doi.org/10.1093/neuonc/noab094.
Article
PubMed
PubMed Central
Google Scholar
Amaral T, Kiecker F, Schaefer S, et al. Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients. J Immunother Cancer. 2020. https://doi.org/10.1136/jitc-2019-000333.
Article
PubMed
PubMed Central
Google Scholar
Dimitriou F, Zaremba A, Allayous C, et al. Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response. Eur J Cancer. 2021;149:37–48. https://doi.org/10.1016/j.ejca.2021.02.037.
CAS
Article
PubMed
Google Scholar
Rangachari D, Yamaguchi N, VanderLaan PA, et al. Brain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancers. Lung Cancer. 2015. https://doi.org/10.1016/j.lungcan.2015.01.020.
Article
PubMed
Google Scholar
Heon S, Yeap BY, Lindeman NI, et al. The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations. Clin cancer Res an Off J Am Assoc Cancer Res. 2012;18(16):4406–14. https://doi.org/10.1158/1078-0432.CCR-12-0357.
CAS
Article
Google Scholar
Su P-L, Wu Y-L, Chang W-Y, et al. Preventing and treating brain metastases with three first-line EGFR-tyrosine kinase inhibitors in patients with EGFR mutation-positive advanced non-small cell lung cancer. Ther Adv Med Oncol. 2018;10:1758835918797589. https://doi.org/10.1177/1758835918797589.
CAS
Article
PubMed
PubMed Central
Google Scholar
Wu Y-L, Ahn M-J, Garassino MC, et al. CNS efficacy of osimertinib in patients with T790M-positive advanced non-small-cell lung cancer: data from a randomized phase III trial (AURA3). J Clin Oncol Off J Am Soc Clin Oncol. 2018;36(26):2702–9. https://doi.org/10.1200/JCO.2018.77.9363.
CAS
Article
Google Scholar
Goss G, Tsai C-M, Shepherd FA, et al. CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials. Ann Oncol Off J Eur Soc Med Oncol. 2018;29(3):687–93. https://doi.org/10.1093/annonc/mdx820.
CAS
Article
Google Scholar
Reungwetwattana T, Nakagawa K, Cho BC, et al. CNS Response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2018. https://doi.org/10.1200/JCO.2018.78.3118.
Article
Google Scholar
Solomon BJ, Mok T, Kim D-W, et al. First-line crizotinib versus chemotherapy in ALK -positive lung cancer. N Engl J Med. 2014. https://doi.org/10.1056/NEJMoa1408440.
Article
PubMed
PubMed Central
Google Scholar
Solomon BJ, Cappuzzo F, Felip E, et al. Intracranial efficacy of crizotinib versus chemotherapy in patients with advanced ALK -positive non–small-cell lung cancer: results from PROFILE 1014. J Clin Oncol. 2016. https://doi.org/10.1200/JCO.2015.63.5888.
Article
PubMed
PubMed Central
Google Scholar
Soria J-C, Tan DSW, Chiari R, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet. 2017. https://doi.org/10.1016/S0140-6736(17)30123-X.
Article
PubMed
Google Scholar
Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated ALK -positive non–small-cell lung cancer. N Engl J Med. 2017. https://doi.org/10.1056/NEJMoa1704795.
Article
PubMed
PubMed Central
Google Scholar
Gadgeel S, Peters S, Mok T, et al. Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study. Ann Oncol. 2018. https://doi.org/10.1093/annonc/mdy405.
Article
PubMed
PubMed Central
Google Scholar
Camidge DR, Kim HR, Ahn M-J, et al. Brigatinib versus crizotinib in ALK -positive non–small-cell lung cancer. N Engl J Med. 2018;379(21):2027–39. https://doi.org/10.1056/NEJMoa1810171.
CAS
Article
PubMed
Google Scholar
Shaw AT, Bauer TM, de Marinis F, et al. First-line lorlatinib or crizotinib in advanced ALK -positive lung cancer. N Engl J Med. 2020. https://doi.org/10.1056/NEJMoa2027187.
Article
PubMed
PubMed Central
Google Scholar
Shaw AT, Kim TM, Crinò L, et al. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2017. https://doi.org/10.1016/S1470-2045(17)30339-X.
Article
PubMed
PubMed Central
Google Scholar
Novello S, Mazières J, Oh I-J, et al. Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study. Ann Oncol. 2018. https://doi.org/10.1093/annonc/mdy121.
Article
PubMed
PubMed Central
Google Scholar
Kim D-W, Tiseo M, Ahn M-J, et al. Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non–small-cell lung cancer: a randomized, multicenter phase II trial. J Clin Oncol. 2017. https://doi.org/10.1200/JCO.2016.71.5904.
Article
PubMed
PubMed Central
Google Scholar
Huber RM, Hansen KH, Paz-Ares Rodríguez L, et al. Brigatinib in crizotinib-refractory ALK+ NSCLC: 2-year follow-up on systemic and intracranial outcomes in the phase 2 ALTA trial. J Thorac Oncol. 2020. https://doi.org/10.1016/j.jtho.2019.11.004.
Article
PubMed
Google Scholar
Felip E, Shaw AT, Bearz A, et al. Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs. Ann Oncol. 2021. https://doi.org/10.1016/j.annonc.2021.02.012.
Article
PubMed
Google Scholar
Gainor JF, Tseng D, Yoda S, et al. Patterns of metastatic spread and mechanisms of resistance to crizotinib in ROS1 -positive non–small-cell lung cancer. JCO Precis Oncol. 2017. https://doi.org/10.1200/PO.17.00063.
Article
PubMed
PubMed Central
Google Scholar
Shaw AT, Riely GJ, Bang Y-J, et al. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. Ann Oncol. 2019. https://doi.org/10.1093/annonc/mdz131.
Article
PubMed
PubMed Central
Google Scholar
Shaw AT, Solomon BJ, Chiari R, et al. Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial. Lancet Oncol. 2019. https://doi.org/10.1016/S1470-2045(19)30655-2.
Article
PubMed
PubMed Central
Google Scholar
Drilon A, Siena S, Dziadziuszko R, et al. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials. Lancet Oncol. 2020. https://doi.org/10.1016/S1470-2045(19)30690-4.
Article
PubMed
PubMed Central
Google Scholar
Mohile SG, Mohamed MR, Culakova E, et al. A geriatric assessment (GA) intervention to reduce treatment toxicity in older patients with advanced cancer: A University of Rochester Cancer Center NCI community oncology research program cluster randomized clinical trial (CRCT). J Clin Oncol. 2020;38(15_suppl):12009. https://doi.org/10.1200/JCO.2020.38.15_suppl.12009.
Article
Google Scholar
Li D, Sun C-L, Kim H, et al. Geriatric assessment-driven intervention (GAIN) on chemotherapy toxicity in older adults with cancer: a randomized controlled trial. J Clin Oncol. 2020;38(15_suppl):12010. https://doi.org/10.1200/JCO.2020.38.15_suppl.12010.
Article
Google Scholar
Soo W-K, King M, Pope A, Parente P, Darzins P, Davis ID. Integrated geriatric assessment and treatment (INTEGERATE) in older people with cancer planned for systemic anticancer therapy. J Clin Oncol. 2020;38(15_suppl):12011. https://doi.org/10.1200/JCO.2020.38.15_suppl.12011.
Article
Google Scholar
Rades D, Pluemer A, Veninga T, Schild SE. Comparison of different treatment approaches for one to two brain metastases in elderly patients. Strahlenther Onkol. 2008;184(11):565–71. https://doi.org/10.1007/s00066-008-1908-1.
Article
PubMed
Google Scholar
Orimo H, Ito H, Suzuki T, Araki A, Hosoi T, Sawabe M. Reviewing the definition of “elderly.” Geriatr Gerontol Int. 2006;6(3):149–58. https://doi.org/10.1111/j.1447-0594.2006.00341.x.
Article
Google Scholar
Rades D, Nguyen T, Schild SE. Elderly patients with single brain metastasis—overall survival after surgery plus whole-brain irradiation and a radiation boost. In Vivo. 2020;34(3):1421–5. https://doi.org/10.21873/invivo.11923.
Article
PubMed
PubMed Central
Google Scholar
Rades D, Nguyen T, Janssen S, Schild SE. An instrument to guide physicians when estimating the survival of elderly patients with brain metastasis from gynecological cancer. Anticancer Res. 2020;40(4):2257–60. https://doi.org/10.21873/anticanres.14188.
Article
PubMed
Google Scholar
Sperduto PW, Mesko S, Li J, et al. Survival in patients with brain metastases: summary report on the updated diagnosis-specific graded prognostic assessment and definition of the eligibility quotient. J Clin Oncol Off J Am Soc Clin Oncol. 2020;38(32):3773–84. https://doi.org/10.1200/JCO.20.01255.
CAS
Article
Google Scholar